TY - JOUR
T1 - Prognostic markers in renal cell carcinoma
T2 - A focus on the 'mammalian target of rapamycin' pathway
AU - Youssef, Ramy F.
AU - Cost, Nicholas G.
AU - Darwish, Oussama M.
AU - Margulis, Vitaly
PY - 2012/6
Y1 - 2012/6
N2 - Objectives: Increased knowledge about the molecular pathways involved in tumorigenesis has led to the discovery of new prognostic molecular markers and development of novel targeted therapies for renal cell carcinoma (RCC). In this review we describe the prognostic markers of RCC and highlight the areas of recent discovery with a focus on the mammalian target of rapamycin (mTOR) pathway. Methods: We reviewed previous reports, using PubMed with the search terms 'renal cell carcinoma', 'molecular markers', 'prognosis', 'outcomes' and 'mammalian target of rapamycin pathway' published in the last two decades. We created a library of 100 references and focused on presenting the recent advances in the field. Results: Growing evidence suggests that mTOR deregulation is associated with many types of human cancer, including RCC. Consequently, temsirolimus and everolimus, which target mTOR, are approved for treating advanced RCC. There is a demand to integrate clinical, pathological and molecular markers into accurate prognostic models to provide patients with the most personalised cancer care possible. Conclusions: The mTOR pathway is highly implicated in RCC tumorigenesis and progression, and its constituents might represent a promising prognostic tool and target for treating RCC. Combining newly discovered molecular markers with classic clinicopathological prognostics might potentially improve the management of RCC.
AB - Objectives: Increased knowledge about the molecular pathways involved in tumorigenesis has led to the discovery of new prognostic molecular markers and development of novel targeted therapies for renal cell carcinoma (RCC). In this review we describe the prognostic markers of RCC and highlight the areas of recent discovery with a focus on the mammalian target of rapamycin (mTOR) pathway. Methods: We reviewed previous reports, using PubMed with the search terms 'renal cell carcinoma', 'molecular markers', 'prognosis', 'outcomes' and 'mammalian target of rapamycin pathway' published in the last two decades. We created a library of 100 references and focused on presenting the recent advances in the field. Results: Growing evidence suggests that mTOR deregulation is associated with many types of human cancer, including RCC. Consequently, temsirolimus and everolimus, which target mTOR, are approved for treating advanced RCC. There is a demand to integrate clinical, pathological and molecular markers into accurate prognostic models to provide patients with the most personalised cancer care possible. Conclusions: The mTOR pathway is highly implicated in RCC tumorigenesis and progression, and its constituents might represent a promising prognostic tool and target for treating RCC. Combining newly discovered molecular markers with classic clinicopathological prognostics might potentially improve the management of RCC.
KW - Molecular markers
KW - Prognostic
KW - Renal cell carcinoma
KW - mTOR
UR - http://www.scopus.com/inward/record.url?scp=84864440385&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84864440385&partnerID=8YFLogxK
U2 - 10.1016/j.aju.2012.02.005
DO - 10.1016/j.aju.2012.02.005
M3 - Review article
C2 - 26558012
AN - SCOPUS:84864440385
SN - 2090-598X
VL - 10
SP - 110
EP - 117
JO - Arab Journal of Urology
JF - Arab Journal of Urology
IS - 2
ER -